ClinicalTrials.gg

Idiopathic Hypersomnia clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 53 studies for Idiopathic Hypersomnia across more than 10 countries. 24 are recruiting or about to start. 36 of them are mainly about Idiopathic Hypersomnia (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17.

Status

Completed
26
Recruiting
17
Not yet recruiting
6
Enrolling by invitation
1
Withdrawn
1
Status unknown
1

Phase

Phase 2
16
Phase 3
9
Phase 4
3
Phase 1
3

Where

United States
30
France
18
Spain
6
Italy
5
Australia
4
Canada
4

Who develops what

Add Idiopathic Hypersomnia to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 5 programs from 5 companies, 5 with this as their studies’ main aim; 4 with a live phase 3 study; 4 primary completions in the next 12 months. Compare Alkermes, Eli Lilly and Harmony Biosciences here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

None given by two companies or more yet.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

The 5 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (4)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Nov 2026 est.alixorexton · Alkermes, Inc. · Phase 2 main aimNCT06843590 A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Idiopathic Hypersomnia — primary endpoint: Change in Epworth Sleepiness Scale (ESS) from baseline to Week 8 by dose level · 126 enrolled
  • 30 Nov 2026 est.TAK-360 · Takeda · Phase 2 main aimNCT06812078 A Study of TAK-360 in Adults With Idiopathic Hypersomnia — primary endpoint: Number of Participants With at Least One Treatment-emergent Adverse Events (TEAEs) · 96 enrolled
  • Dec 2026 est.ORX750 · Eli Lilly and Company · Phase 2 main aimNCT06752668 A Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia — primary endpoint: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs · 248 enrolled

1 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Idiopathic Hypersomnia studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Coming up

10studies finish main data collection within a year1 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 10, phase 3 first

Who these studies take

Of the 17 Idiopathic Hypersomnia studies recruiting now, 4 (24%) set no upper age limit and 12 (71%) stop at 75 or younger. 2 (12%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 4 (24%) take healthy volunteers.

Recruiting studies that take each age, of 17
AgeWomenMen
102 (12%)2 (12%)
1817 (100%)17 (100%)
3017 (100%)17 (100%)
4017 (100%)17 (100%)
5016 (94%)16 (94%)
6515 (88%)15 (88%)
756 (35%)6 (35%)
855 (29%)5 (29%)

Across all 53 studies, recruiting or not: 64% stop at 75 or younger and 40% at 65; 15% take children; 0% are for women only and 4% for men only; 23% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 53. Browse all 53 → or search them.